Constipation News and Research

Latest Constipation News and Research

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

13 Oct 2014

RBX2660 drug candidate highly effective against recurrent Clostridium difficile infection

Rebiotix Inc. announced today that results of the Phase 2 PUNCH CD Study found that the overall efficacy of RBX2660 in the treatment of recurrent Clostridium difficile infection was 87.1%. The study also found that administration of RBX2660 was well-tolerated and demonstrated satisfactory safety in the 60-day interim analysis.

9 Oct 2014

Early potty training linked to increased risk of developing daytime wetting problems later

Children who start toilet training before age 2 have a three times higher risk of developing daytime wetting problems later, according to new research at Wake Forest Baptist Medical Center.

8 Oct 2014

Depression contributes to abnormal pain processes in IBS patients

High rates of anxiety and depression amongst patients with irritable bowel syndrome (IBS) have led many researchers to believe there could be a causal relationship between psychological factors and IBS symptoms. Now, scientists in Germany have found clear evidence that patients with IBS process pain signals from the gut abnormally, and that disturbed brain responses to pain are particularly pronounced in patients with more depression symptoms.

3 Oct 2014

Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C).

1 Oct 2014

Adding common epilepsy drug to morphine can result in better pain control, say IU researchers

Adding a common epilepsy drug to a morphine regimen can result in better pain control with fewer side effects. Moreover, the combination can reduce the dosage of the opioid needed to be effective, according to a team of pain researchers at Indiana University.

17 Sep 2014

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Nektar Therapeutics reported today that partner AstraZeneca today announced that the US Food and Drug Administration (FDA) approved MOVANTIK (naloxegol) tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC), in adult patients with chronic, non-cancer pain.

16 Sep 2014

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough.

15 Sep 2014

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

11 Sep 2014

FDA approves Ferric Citrate for control of serum phosphorus levels in CKD patients on dialysis

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved Ferric Citrate (formerly known as Zerenex) for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

6 Sep 2014

Synthetic announces positive results from final preclinical toxicology study of SYN-004

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive results from its final preclinical toxicology study of SYN-004.

2 Sep 2014

Auriculotherapy may help in managing chronic constipation

Nearly 1 in 6 adults worldwide may suffer from chronic constipation and, over time, the disorder can cause serious complications. Auriculotherapy, a form of acupuncture that involves stimulating targeted points on the outer ear, may help in managing constipation.

26 Aug 2014

Experts available to share tips on prevention of ovarian cancer

Ovarian cancer is the fourth leading cause of death in American women, with about 22,000 diagnosed and 14,000 dying from the disease each year. September is Ovarian Cancer Awareness month and Mount Sinai experts are sharing tips on prevention.

26 Aug 2014

Young girls with vulvitis may be at increased risk of developing urinary tract infections

Young girls with an intense, red, itchy rash on their outer genital organs may be at increased risk of developing urinary tract infections (UTIs), according to new research from Wake Forest Baptist Medical Center. The treatment may be as simple as better hygiene and avoiding potential irritants such as bubble baths and swimming pools.

22 Aug 2014

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS).

13 Aug 2014

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its SYN-005 for the treatment of Pertussis will be highlighted at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 5-9, in Washington D.C.

12 Aug 2014

Anti-cholinergic drugs could be responsible for decline in cognitive, physical function in elderly patients

Drugs widely prescribed to the elderly could be responsible for a decline in cognitive and physical function according to research from the University of East Anglia and the Regenstrief Institute.

31 Jul 2014

EMA CHMP adopts positive opinion for Janssen’s IMBRUVICA to treat CLL and MCL

Janssen-Cilag International NV announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the granting of a marketing authorisation for IMBRUVICA (ibrutinib) in the European Union.

29 Jul 2014

EMA recommends full marketing approval for IMBRUVICA in the European Union

Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA (ibrutinib) in the European Union.

25 Jul 2014

Study examines mechanism of bone-protective properties of California dried plums

Fifty-seven million Americans suffer from low bone density or osteoporosis, a disease which causes bones to become so weak and brittle that even a minor fall or other stresses may cause fractures.

17 Jul 2014

Constipation News and Research

Latest Constipation News and Research

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

RBX2660 drug candidate highly effective against recurrent Clostridium difficile infection

Early potty training linked to increased risk of developing daytime wetting problems later

Depression contributes to abnormal pain processes in IBS patients

Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Adding common epilepsy drug to morphine can result in better pain control, say IU researchers

MOVANTIK tablets get FDA approval for treatment of OIC in patients with chronic, non-cancer pain

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

FDA approves Contrave extended-release tablets for chronic weight management

FDA approves Ferric Citrate for control of serum phosphorus levels in CKD patients on dialysis

Synthetic announces positive results from final preclinical toxicology study of SYN-004

Auriculotherapy may help in managing chronic constipation

Experts available to share tips on prevention of ovarian cancer

Young girls with vulvitis may be at increased risk of developing urinary tract infections

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics' SYN-005 antibody for Pertussis treatment to be highlighted at ICAAC 2014

Anti-cholinergic drugs could be responsible for decline in cognitive, physical function in elderly patients

EMA CHMP adopts positive opinion for Janssen’s IMBRUVICA to treat CLL and MCL

EMA recommends full marketing approval for IMBRUVICA in the European Union

Study examines mechanism of bone-protective properties of California dried plums

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Constipation News and Research

Latest Constipation News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in